References
1. Chernow B, Zaloga G, McFadden E, et al. Hypocalcemia in critically ill patients. Crit Care Med 1982; 10: 848–851.
2. Zivin J, Gooley T, Zager RA, et al. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis 2001; 37: 689–698.
3. Zaloga GP. Hypocalcemia in critically ill patients. Crit Care Med 1992; 20: 251–262.
4. Zaloga GP. Hypocalcemic crisis. Crit Care Clin 1991; 7: 191–200.
5. Forser J, Querusio L, Burchard KW, et al. Hypercalcemia in critically ill surgical patients. Ann Surg 1985; 202: 512–518.
6. Martinez FJ, Lash RW. Endocrinologic and metabolic complications in the intensive care unit. Clin Chest Med 1999; 20: 401–421.
7. Weis-Guillet EM, Takala J, Jakob SM. Diagnosis and management of electrolyte emergencies. Best Pract Res Clin Endocrinol Metab 2003; 17: 623–651.
8. Slomp J, van der Voort PH, Gerritsen RT, et al. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003; 31: 1389–1393.
9. Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4: 643–646.
10. Dickerson RN, Alexander KH, Minard G, et al. Accuracy of methods to estimate ionized and “corrected” serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr 2004; 28: 133–141.
11. Wermers RA, Kearns AE, Jenkins GD, et al. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007; 120: 911.e9–e15.
12. Wisneski LA, Croom WP, Silva OL, et al. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978; 24: 219–222.
13. Sekine M, Takami H. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Oncol Rep 1998; 5: 197–199.
14. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297–304.
15. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinic trials. J Clin Oncol 2001; 19: 558–567.
16. Body JJ, Bouillon R. Emergencies of calcium homeostasis. Rev Endocr Metab Disord 2003; 4: 167–175.
17. Krahn J, Lou H. Ionized calcium: whole blood, plasma or serum? Clin Lab 2008; 54: 185–189.
18. Desai TK, Carlson RW, Thill-Baharozian M, et al. A direct relationship between ionized calcium and arterial pressure among patients in an intensive care unit. Crit Care Med 1988; 16: 578–582.
19. Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med 1988; 84: 209–214.
20. Wilson RF, Binkley LE, Sabo FM, et al. Electrolyte and acid-base changes with massive blood transfusions. Am Surg 1992; 58: 535–544.
21. Benoit SR, Mendelsohn AB, Nourjah P, et al. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005; 12: 363.
22. Bayer R, Schwarzmaier J, Pernice R. Basic mechanisms underlying prenylamine-induced “torsade de pointes”: differences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin 1988; 11: 254–272.
23. Warshaw AL, Lee KH, Napier TW, et al. Depression of serum calcium by increased plasma free fatty acids in the rat: a mechanism for hypocalcemia in acute pancreatitis. Gastroenterology 1985; 89: 814–820.
24. Imrie CW, Allam BF, Ferguson JC. Hypocalcaemia of acute pancreatits: the effect of hypoalbuminaemia. Curr Med Res Opin 1976; 4: 101–116.
25. Ryzen E, Rude RK. Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia. West J Med 1990; 152: 145–148.
26. Graber ML. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1995; 25: 973.
27. Hsu HJ, Wu MS. Extreme hyperphosphatemia and hypocalcemic coma associated with phosphate enema. Intern Med 2008; 47: 642–646.
28. Bringhurst FR, Demay MB, Kronenburg HM. Hormones and disorders of mineral metabolism, in Kronenburg HM (ed). Williams Textbook of Endocrinology. Philadelphia, Saunders, 2008, ed 11, p 1246.
29. Sedlacek M, Schoolwerth AC, Remillard BD. Electrolyte disturbances in the intensive care unit. Semin Dial 2006; 19: 496–501.
30. Sharatt CL, Gilbert CJ, Cornes MC, et al. EDTA sample contamination is common and often undetected, putting patients at unnecessary risk of harm. Int J Clin Pract 2009; 63: 1126–1127.
31. Williams SF, Meek SE, Moraghan TJ. Spurious hypocalcemia after gadodiamide administration. Mayo Clin Proc 2005; 80: 1655–1657.
32. Nanji AA, Denegri JF. Hypomagnesemia associated with gentamicin therapy. Drug Intell Clin Pharm 1984; 18: 596–598.
33. Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother 2009; 43: 1419–1425.
34. Kankirawatana S, Huang ST, Marques MB. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange. J Clin Apher 2007; 22: 265–269.
35. Guillaume MP, Karmali R, Bergmann P, et al. Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS. Clin Infect Dis 1997; 25: 932–933.
36. Huang HH, Yen DH, Wu ML. Acute Erycibe henryi Prain (“Ting Kung Teng”) poisoning. Clin Toxicol (Phila) 2006; 44: 71–75.
37. Jin UH, Kim DI, Lee TK. Herbal formulation, Yukmi-jihang-tang-Jajage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression. J Ethnopharmacol 2006; 106: 333–343.
38. Valsamis HA, Arora SK, Labban B. Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 2006; 3: 36–47.
39. Friedman HZ, Langman CB, Favus MJ. Vitamin D metabolism and osteomalacia in cystic fibrosis. Gastroenterology 1985; 88: 808–813.
40. Wills MR, Savory J. Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci 1984; 14: 189–197.
41. Bushinsky DA, Monk R. Calcium. Lancet 1998; 352: 306–311.
42. Movilli E, Zani R, Carli O. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. Nephron 2001; 87: 257–262.
43. Murros J, Luomanmaki K. A case of hypocalcemia, heart failure and exceptional repolarization disturbances. Acta Med Scand 1980; 208: 133–136.
44. Muller B, Becker KL, Kranzlin M, et al. Disordered calcium homeostasis of sepsis: association with calcitonin precursors. Eur J Clin Invest 2000; 30: 823–831.
45. Lind L, Bucht E, Ljunghall S. Pronounced elevation in circulating calcitonin in critical care patients is related to the severity of illness and survival. Intensive Care Med 1995; 21: 63–66.
46. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors in the predication of severity of acute pancreatitis on the day of admission. Br J Surg 2003; 90: 197–204.
47. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993; 22: 363–375.
48. Kraft MD, Btaiche IF, Sacks GS, et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005; 62: 1663–1683.
49. Lin CY, Hsieh KC, Yeh MC, et al. Skin necrosis after intravenous calcium chloride administration as a complication of parathyroidectomy for secondary hyperparathyroidism: report of four cases. Surg Today 2007; 37: 778–781.
50. Larralde M, Giachetti A, Kowalczuk A, et al. Calcinosis cutis following liver transplantation in pediatric patient. Pediatr Dermatol 2003; 20: 225–228.
51. Ehsani AH, Abedini R, Ghiasi M, et al. Calcinosis cutis complicating liver transplantation. Dermatol Online J 2006; 12: 23.
52. Jucgla A, Sais G, Curco N, et al. Calcinosis cutis following liver transplantation: a complication of intravenous calcium administration. Br J Dermatol 1995; 132: 275–278.
53. Dickerson RN, Morgan LG, Cauthen AD, et al. Treatment of acute hypocalcemia in critically ill multiple-trauma patients. JPEN J Parenter Enteral Nutr 2005; 29: 436–441.
54. Dickerson RN, Morgan LM, Croce MA, et al. Treatment of moderate to severe acute hypocalcemia in critically ill trauma patients. JPEN J Parenter Enteral Nutr 2007; 31: 228–233.
55. Dickerson RN, Morgan LM, Croce MA, et al. Dose-dependent characteristics of intravenous calcium therapy for hypocalcemic critically ill trauma patients receiving specialized nutritional support. Nutrition 2007; 23: 9–15.
56. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 68: 108G–118G.
57. Egi M, Nichol A, Stachowski E, et al. Ionized calcium concentration and outcome in critical illness. Crit Care Med 2011; 39: 314–321.
58. Forsythe RM, Wessel CB, Billiar TR, et al. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev 2008; 4: CD006163.
59. Zaloga GP, Sager A, Black KW, et al. Low dose calcium administration increases mortality during septic peritonitis in rats. Circ Shock 1992; 37: 226–229.
60. Davis KD, Attie MF. Management of server hypercalcemia. Crit Care Clin 1991; 7: 175–190.
61. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008; 35: 215–217.
62. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid-like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989; 111: 807–812.
63. Bridgewater JA, Ratcliffe WA, Bundred NJ, et al. Malignant phaeochromocytoma and hypercalcemia. Postgrad Med J 1993; 69: 77–79.
64. Kimura S, Nishimura Y, Yamaguchi K, et al. A case of pheochromocytoma producing parathyroid hormone-related protein and presenting with hypercalcemia. J Clin Endocrinol Metab 1990; 70: 1559–1563.
65. Fuss M, Pepersack T, Gillet C, et al. Calcium and vitamin D metabolism in granulomatous diseases. Clin Rheumatol 1992; 11: 28–36.
66. Igbal AA, Burgess EH, Gallina DL, et al. Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract 2003; 9: 517–521.
67. Glemarec J, Varin S, Rodet D, et al. Hypercalcemia in a patient with tuberculous adrenal insufficiency. Joint Bone Spine 2002; 69: 88–91.
68. Katahira M, Yamada T, Kawai M. A case of Cushing syndrome with both secondary hypothyroidism and hypercalcemia due to postoperative adrenal insufficiency. Endocr J 2004; 51: 105–113.
69. Agus ZS, Wasserstein A, Goldfarb S. Disorders of calcium and magnesium homeostasis. Am J Med 1982; 72: 473–488.
70. Khandwala HM, Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12: 54–58.
71. Arumugam GP, Sudravel S, Shanthi P, et al. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 2006; 24: 243–247.
72. McPherson ML, Prince SR, Atamer ER, et al. Theophylline-induced hypercalcemia. Ann Intern Med 1986; 105: 52–54.
73. Beall DP, Henslee HB, Webb HR, et al. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006; 331: 233–234.
74. Waked A, Geara A, El-Imad B. Hypercalcemia, metabolic alkalosis and renal failure secondary to calcium bicarbonate intake for osteoporosis prevention—“modern” milk alkali syndrome: a case report. Cases J 2009; 2: 6188.
75. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008; 149: 259–263.
76. Pamidronate disodium (adult dosing). Micromedex 2.0. Philadelphia, Thompson Reuters.
77. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385–1393.
78. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 2008; 38: 635–637.
79. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799–1809.
80. Roldan EJ, Kerzberg EM, Castelli G, et al. Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients. Medicina (B Aires) 1996; 56: 133–137.
81. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990; 46: S26–S30.
82. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28: 627–636.
83. Kristensen B, Ejlertsen B, Holmegaard SN, et al. Prednisolone in the treatment of severe malignant hypercalcemia in metastatic breast cancer: a randomized study. J Intern Med 1992; 232: 237–245.
84. Davidson TG. Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 2001; 58 (3 suppl): S8–S15.
85. Rubin MR, Bruce JN, Khandji AG, et al. Sarcoidosis with a pituitary adenoma. Pituitary 2001; 4: 195–202.
86. Robin J, Fintel B, Pikovskaya O, et al. Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of literature. J Med Case Reports 2008; 2: 229.
87. Camus C, Charassee C, Jouannic-Montier I, et al. Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia. Intensive Care Med 1996; 22: 116–121.
88. Wang CC, Chen YC, Shiang JC, et al. Hypercalcemic crisis successfully treated with prompt calcium-free hemodialysis. Am J Emerg Med 2009; 27: 1174.e1–e3.
89. Tan HK, Bellomo R, M’Pisi DA, et al. Ionized serum calcium levels during acute renal failure: intermittent hemodialysis vs continuous hemodiafiltration. Ren Fail 2002; 24: 19–27.